CN Mobile Logo


Breast Cancer

Too Many DCIS Patients Get Axillary Lymph Node Dissection

No benefit of axillary lymph node evaluation has been shown for women with DCIS, yet this lymph node analysis is still often performed in these patients. Image © Blamb / Shutterstock.com.

Breast Cancer

Serum matrix metalloproteinase 9 (MMP-9) and HER2 extra-cellular domain (HER2-ECD) might be predictive biomarkers for the metastasis of breast cancer to the brain, according to a case-control study.

Researchers have developed a blood-based assay that detects ESR1 mutations in circulating tumor DNA and could predict treatment failure in breast cancer patients.

Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.

The use of afatinib failed to show a benefit in HER2-positive breast cancer patients with progressive brain metastases.

Identifying breast cancer patients who are at low risk for chemotherapy-induced nausea and vomiting before the start of treatment may help avoid unnecessary use of antiemetic medications without compromising quality of care.

We acknowledge that the “more is better” approach may not always hold true. For example, preclinical data provided a rationale for combining pertuzumab with T-DM1, but recent reports suggest that this strategy may not prove more effective than single-agent T-DM1 therapy in the clinic.

The preferred status of CLEOPATRA-like regimens in the first-line HER2-positive metastatic breast cancer setting has recently been challenged by antibody-drug conjugate regimens based on ado-trastuzumab emtansine (T-DM1).


Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.